Show simple item record

dc.contributor.authorMcNamara, Mairead G
dc.contributor.authorLopes, A.
dc.contributor.authorWasan, H.
dc.contributor.authorMalka, D.
dc.contributor.authorGoldstein, D.
dc.contributor.authorShannon, J.
dc.contributor.authorOkusaka, T.
dc.contributor.authorKnox, J. J.
dc.contributor.authorWagner, A. D.
dc.contributor.authorAndre, T.
dc.contributor.authorCunningham, D.
dc.contributor.authorMoehler, M.
dc.contributor.authorJensen, L. H.
dc.contributor.authorKoeberle, D.
dc.contributor.authorBekaii-Saab, T.
dc.contributor.authorBridgewater, J.
dc.contributor.authorValle, Juan W
dc.date.accessioned2020-06-16T11:03:15Z
dc.date.available2020-06-16T11:03:15Z
dc.date.issued2020en
dc.identifier.citationM. G. McNamara, A. Lopes, H. Wasan et al. Landmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract cancer. J Hepatol. 2020.en
dc.identifier.pmid32446715en
dc.identifier.doi10.1016/j.jhep.2020.05.014en
dc.identifier.urihttp://hdl.handle.net/10541/623027
dc.description.abstractBACKGROUND: Inclusion of all patients with advanced biliary tract cancer (aBTC), irrespective of anatomic location, in prospective trials, is debated. Survival rates from landmark analysis offer more relevant information once patients have survived for some time. AIM: assess survival impact of BTC anatomic site origin and landmark survival (LS). PATIENTS AND METHODS: Patients enrolled into prospective first-line aBTC clinical trials were included. OS was analysed using Cox-proportional-hazard-regression; LS and 95% confidence intervals (CIs) were calculated. RESULTS: Overall: 1333 patients included (Jan 97-Dec 15); median age 63-years (range 23-85); 46%-male; 84%-ECOG-PS0/1; 25%-locally-advanced (LA), 72%-metastatic, 3%-not reported (NR); gallbladder-(GBC): 385 (29%), cholangiocarcinoma not-specified-(CCA-NS): 363 (27%), extrahepatic-(EHC): 247 (19%), intrahepatic-(IHC): 209 (16%), ampulla: 53 (4%), 76 (6%) NR. Treatment was mono-chemotherapy: 310-(23%), cisplatin/gemcitabine: 482-(36%), other combination: 520-(39%), NR: 21-(2%). Median OS: 10.2-months (95%-CI 9.6-10.9). All sites (treatment-adjusted) had decreased risk of death vs GBC: EHC-(P<.001), IHC-(P<.002), CCA-NS-(P<.003), ampulla-(P=.003). This reduced risk vs GBC was maintained in those receiving cisplatin/gemcitabine in EHC-(P<.001) and IHC-(P<.001), but not in CCA-NS-(P=.82) or ampulla-(P=.96). Probabilities of surviving an additional year given survival to 1, 2, 3, and 4 years post-trial registration were 37%, 45%, 61%, and 63% respectively. For patients who survived 1 year; those receiving combination therapy vs mono (P=.008) (acknowledging potential selection bias), and those with IHC and CCA-NS vs GBC had better LS (both P<.05). Metastatic stage vs LA was associated with shorter LS (P=.002). ECOG-PS and gender had no evidence of effect on LS (P.05en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.jhep.2020.05.014en
dc.titleLandmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract canceren
dc.typeArticleen
dc.contributor.departmentDivision of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester M20 4BX,en
dc.identifier.journalJournal of Hepatologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record